• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Gossamer Bio Inc (NQ: GOSS )

    1.020 -0.100 (-8.93%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 29, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,325,487
    Open 1.120
    Bid (Size) 1.020 (4)
    Ask (Size) 1.030 (3)
    Prev. Close 1.120
    Today's Range 1.000 - 1.120
    52wk Range 0.4525 - 1.600
    Shares Outstanding 75,993,532
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
    Oppenheimer initiated coverage on Gossamer Bio, highlighting seralutinib's clean long-term safety profile for pulmonary arterial hypertension. Seralutinib shows potential in underserved markets. 
    Via Benzinga
    Gossamer Bio And 2 Other Stocks Under $2 Insiders Are Buying
    Via Benzinga

    Performance

    YTD
    +5.15%
    +5.15%
    1 Month
    +7.64%
    +7.64%
    3 Month
    +46.49%
    +46.49%
    6 Month
    +18.07%
    +18.07%
    1 Year
    -24.44%
    -24.44%

    More News

    Read More
    Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street
    Via InvestorPlace
    HC Wainwright & Co. Maintains Buy Rating for Gossamer Bio: Here's What You Need To Know
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
    From Gossamer Bio, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Gossamer Bio, Inc.
    Via Business Wire
    GOSS Stock Earnings: Gossamer Bio Misses EPS for Q1 2024
    Via InvestorPlace
    Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide
    Via Benzinga
    Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
    From Gossamer Bio, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
    From Gossamer Bio, Inc.
    Via Business Wire
    Goldman Sachs Maintains Buy Rating for Gossamer Bio: Here's What You Need To Know
    Via Benzinga
    GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023
    Via InvestorPlace
    Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
    From Gossamer Bio, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    7 Micro-Cap Stocks That Could Majorly Surprise Investors
    Via InvestorPlace
    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Gossamer Bio, Inc.
    Via Business Wire
    Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.